Mink presents clinical data on allogeneic inkt cells (agent-797) in severe respiratory distress at the american thoracic society international conference

New york, may 22, 2023 (globe newswire) -- mink therapeutics (nasdaq: inkt), a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today announced presentation of clinical data from its allo-inkts (agent-797) in covid-19 associated acute respiratory distress syndrome (cards) at the american thoracic society (ats) international conference in washington d.c.
INKT Ratings Summary
INKT Quant Ranking